395 related articles for article (PubMed ID: 14617776)
1. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer.
He B; You L; Uematsu K; Zang K; Xu Z; Lee AY; Costello JF; McCormick F; Jablons DM
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14133-8. PubMed ID: 14617776
[TBL] [Abstract][Full Text] [Related]
2. Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer.
He B; You L; Xu Z; Mazieres J; Lee AY; Jablons DM
Clin Lung Cancer; 2004 May; 5(6):366-70. PubMed ID: 15217536
[TBL] [Abstract][Full Text] [Related]
3. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma.
Niwa Y; Kanda H; Shikauchi Y; Saiura A; Matsubara K; Kitagawa T; Yamamoto J; Kubo T; Yoshikawa H
Oncogene; 2005 Sep; 24(42):6406-17. PubMed ID: 16007195
[TBL] [Abstract][Full Text] [Related]
4. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition.
Weber A; Hengge UR; Bardenheuer W; Tischoff I; Sommerer F; Markwarth A; Dietz A; Wittekind C; Tannapfel A
Oncogene; 2005 Oct; 24(44):6699-708. PubMed ID: 16007169
[TBL] [Abstract][Full Text] [Related]
5. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity.
Yoshikawa H; Matsubara K; Qian GS; Jackson P; Groopman JD; Manning JE; Harris CC; Herman JG
Nat Genet; 2001 May; 28(1):29-35. PubMed ID: 11326271
[TBL] [Abstract][Full Text] [Related]
6. Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line.
To KF; Chan MW; Leung WK; Ng EK; Yu J; Bai AH; Lo AW; Chu SH; Tong JH; Lo KW; Sung JJ; Chan FK
Br J Cancer; 2004 Oct; 91(7):1335-41. PubMed ID: 15354212
[TBL] [Abstract][Full Text] [Related]
7. JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3.
Yadav A; Kalita A; Dhillon S; Banerjee K
J Biol Chem; 2005 Sep; 280(36):31830-40. PubMed ID: 15998644
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling.
Lejeune D; Demoulin JB; Renauld JC
Biochem J; 2001 Jan; 353(Pt 1):109-116. PubMed ID: 11115404
[TBL] [Abstract][Full Text] [Related]
9. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma.
Galm O; Yoshikawa H; Esteller M; Osieka R; Herman JG
Blood; 2003 Apr; 101(7):2784-8. PubMed ID: 12456503
[TBL] [Abstract][Full Text] [Related]
10. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.
Isomoto H; Mott JL; Kobayashi S; Werneburg NW; Bronk SF; Haan S; Gores GJ
Gastroenterology; 2007 Jan; 132(1):384-96. PubMed ID: 17241887
[TBL] [Abstract][Full Text] [Related]
11. A family of cytokine-inducible inhibitors of signalling.
Starr R; Willson TA; Viney EM; Murray LJ; Rayner JR; Jenkins BJ; Gonda TJ; Alexander WS; Metcalf D; Nicola NA; Hilton DJ
Nature; 1997 Jun; 387(6636):917-21. PubMed ID: 9202125
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
Lee TL; Yeh J; Van Waes C; Chen Z
Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
[TBL] [Abstract][Full Text] [Related]
13. Cloning and characterization of a functional promoter of the human SOCS-3 gene.
He B; You L; Uematsu K; Matsangou M; Xu Z; He M; McCormick F; Jablons DM
Biochem Biophys Res Commun; 2003 Feb; 301(2):386-91. PubMed ID: 12565872
[TBL] [Abstract][Full Text] [Related]
14. Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter.
Auernhammer CJ; Bousquet C; Melmed S
Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6964-9. PubMed ID: 10359822
[TBL] [Abstract][Full Text] [Related]
15. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction.
Nicholson SE; Willson TA; Farley A; Starr R; Zhang JG; Baca M; Alexander WS; Metcalf D; Hilton DJ; Nicola NA
EMBO J; 1999 Jan; 18(2):375-85. PubMed ID: 9889194
[TBL] [Abstract][Full Text] [Related]
16. Suppressors of cytokine signalling (SOCS): putative modulators of cytokine bioactivity in health and disease.
Diamond P; Doran P; Brady HR; McGinty A
J Nephrol; 2000; 13(1):9-14. PubMed ID: 10720209
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma.
Oshimo Y; Kuraoka K; Nakayama H; Kitadai Y; Yoshida K; Chayama K; Yasui W
Int J Cancer; 2004 Dec; 112(6):1003-9. PubMed ID: 15386345
[TBL] [Abstract][Full Text] [Related]
18. Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway.
Cooney RN
Shock; 2002 Feb; 17(2):83-90. PubMed ID: 11837794
[TBL] [Abstract][Full Text] [Related]
19. Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction.
Losman JA; Chen XP; Hilton D; Rothman P
J Immunol; 1999 Apr; 162(7):3770-4. PubMed ID: 10201892
[TBL] [Abstract][Full Text] [Related]
20. Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion.
Auernhammer CJ; Chesnokova V; Bousquet C; Melmed S
Mol Endocrinol; 1998 Jul; 12(7):954-61. PubMed ID: 9658400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
